News Image

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Provided By GlobeNewswire

Last update: Jan 10, 2025

DUBLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones.

Read more at globenewswire.com

GH RESEARCH PLC

NASDAQ:GHRS (6/4/2025, 8:00:01 PM)

12.43

+0.35 (+2.9%)



Find more stocks in the Stock Screener

Follow ChartMill for more